Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets
Natural gums and mucilage are biocompatible, cheap, readily available, and represent a potential source of excipients. The authors examine the functionality of mucilage extracted from the leaves of Hibiscus rosa-sinensis Linn as an excipient in a sustained-release tablet formulation.

Pharmaceutical Technology
Volume 32, Issue 1


1. A. Boza et al., "Evaluation of Eudrajit RS-PO and Ethocel 100 Matrices for Controlled Released of Lobenzarit Disodium," Drug Dev. Ind. Pharm. 25 (2), 229–233 (1999).

2. S.A. Bravo, M.C. Lamas, and C.J. Salomon, "Swellable Matrices for the Controlled Release of Diclofenac Dodium: Formulation and In-vitro Studies, " Pharm. Dev. Technol. 9 (1), 75–83 (2004).

3. G.M. Khan and Z. Jiabi, "Formulation and In-vitro Evaluation of Ibuprofen-Carbopol 974P-NF Controlled Release Matrix Tablets III: Influence of Co-Excipients on Release Rate of the Drug." J. Controlled Release 54 (2), 185–190 (1998).

4. L. Genc, H. Bilac, and E. Guler, "Studies on Controlled Release Dimenhydrinate from Matrix Tablet Formulations," Pharm. Acta Helv. 74 (1), 43–49 (1999).

5. G.T. Kulkarni et al., "Evaluation of Binding Properties of Plantago ovata and Trigonella foenum graecum Mucilage," Indian Drugs 39 (8), 422–425 (2002).

6. B. Anroop et al.,"Studies on Ocimum gratissimum Seed Mucilage: Evaluation of Suspending Properties," Indian J. Pharm. Sci. 67 (2), 206–209 (2005).

7. P.D. Bharadia et al., "A Preliminary Investigation on Sesbania Gum as a Pharmaceutical Excipient," Int. J. Pharm. Excipients 1(4), 102–105 (2004).

8. H. Pawar, and P.M. D'mello, "Isolation of Seed Gum from Cassia Tora and Preliminary Studies of its Application as a Binder for Tablets," Indian Drugs 41 (8), 465–468 (2004).

9. D. Thomas and R. Fassihi, "Guar Based Monolithic Matrix Systems: Effect of Ionizable and Non-ionizable Substances and Excipients on Gel Dynamics and Release Kinetics," J. Controlled Release 80 (1–3), 45–56 (2003).

10. M.C. Gohel and K.V. Patel, "Formulation Optimization of Dilitazem-HCl Matrix Tablets Containing Modified Ispaghula Husk using Factorial Design," Drug Dev. Ind. Pharm. 23 (11), 1055–1061 (1997).

11. K.P. R. Chowdary, P. Mohapatra, and M.N. Murali Krishna, "Evaluation of Olibanum and its Resin as Rate Controlling Matrix for Controlled Release of Diclofenac," Indian J. Pharm. Sci. 68 (4), 497–500 (2006).

12. J. Mulhbacher, P. Ispas-Szabo, and M.A. Mateeseu, "Cross-linked High Amylase Starch Derivatives for Drug Release II. Swelling Properties and Mechanistic Study," Int. J. Pharm. 278 (2), 231–238 (2004).

13. R.J. Beveridge et al., "Some Structural Features of the Mucilage from the Bark of Ulmus fulva (Slippery Elm Mucilage)," Carbohydrate Res. 9 (4), 429–439 (1969).

14. S. Nurjaya and T.W. Wong, "Effects of Microwave on Drug Release Properties of Matrices of Pectin," Carbohydrate Polym. 62 (3), 245–257 (2005).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here